A carregar...
Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib‐resistant patients, as may provide much longer ov...
Na minha lista:
| Publicado no: | Clin Case Rep |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5538069/ https://ncbi.nlm.nih.gov/pubmed/28781837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1015 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|